Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2024)
Barinthus Biotherapeutics' (BRNS) quarterly EBITDA Margin came in at 62.66% in Q3 2024, up 99.21% on a QoQ basis from 7885.33% in Q2 2023.
Barinthus Biotherapeutics (BRNS) EBITDA Margin (2020 - 2024) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 5 years of EBITDA Margin data on file, last reported at 62.66% in Q3 2024.
- Quarterly EBITDA Margin changed N/A year-over-year to 62.66% in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 471.34% (down 1727.0% YoY) and the FY2024 annual result came in at 454.07%, up 1000902.0% from the prior year.
- EBITDA Margin advanced to 62.66% in Q3 2024, from 7885.33% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 48128.57% in Q2 2021.
- A 5-year average of 104644.19% and a median of 659.43% in 2020 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2021 — EBITDA Margin surged 166952119 bps — and 2022, when it tumbled 166718862 bps.
- Tracing BRNS's EBITDA Margin over 5 years: stood at 2721.19% in 2020, then soared by 61353 bps to 1666800.0% in 2021, then plunged by 100 bps to 388.62% in 2022, then tumbled by 1929 bps to 7885.33% in 2023, then surged by 99 bps to 62.66% in 2024.
- The last three EBITDA Margin figures came in at 62.66% (Q3 2024), 7885.33% (Q2 2023), and 4590.6% (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Barinthus Biotherapeutics | 25.73 Mn | 25.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -62.66% |
| Jun 30, 2023 | -7,885.33% |
| Mar 31, 2023 | -4,590.60% |
| Dec 31, 2022 | -388.62% |
| Sep 30, 2022 | 117.37% |
| Jun 30, 2022 | 77.57% |
| Mar 31, 2022 | 4.35% |
| Dec 31, 2021 | 1,666,800.00% |
| Sep 30, 2021 | -29,136.84% |
| Jun 30, 2021 | -48,128.57% |
| Mar 31, 2021 | -2,870.70% |
| Dec 31, 2020 | -2,721.19% |
| Sep 30, 2020 | -43.92% |
| Jun 30, 2020 | -848.53% |
| Mar 31, 2020 | -659.43% |